Literature DB >> 7427943

Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells.

C T Walsh, R W Craig, R P Agarwal.   

Abstract

Hydroxyurea (0.1 to 10 mM), incubated with L1210 cells in the presence of 1 microM 1-beta-D-arabinofuranosylcytosine (ara-C), produced a concentration- and time-dependent increase in levels of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP). This effect was abolished upon removal of hydroxyurea from cells. The enhancement of ara-CTP by hydroxyurea was observed for concentrations of ara-C ranging from 0.1 to 100 microM. These changes were not associated with alteration in the activity of deoxycytidine kinase, measured in extracts from L1210 cells both with and without deoxycytidine triphosphate. Hydroxyurea did, however, increase the apparent maximum velocity of this enzyme when determined with intact cell preparations, a finding consistent with alteration in endogenous regulation of this enzyme. Four-hr i.v. infusion of hydroxyurea (192 mg/kg/hr) with ara-C (1 mg/kg/hr) into ascites tumor-bearing mice also resulted in increased L1210 cell concentrations of ara-CTP. ara-C levels in plasma and L1210 cells were unaffected by hydroxyurea. Therefore, the enhancement of ara-CTP concentration in vivo, like in vitro, resulted from changes in ara-C conversion in the L1210 cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7427943

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway.

Authors:  L P Colly; D J Richel; M W Arentsen-Honders; M G Kester; P M ter Riet; R Willemze
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

2.  Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model.

Authors:  K S Albain; L J Swinnen; L C Erickson; P J Stiff; R I Fisher
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Deoxypyrimidine-induced inhibition of the cytokinetic effects of 1-beta-D-arabinofuranosyluracil.

Authors:  B Chandrasekaran; T E Kute; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study.

Authors:  Ronald Dubowy; Michael Graham; Nasrollah Hakami; Morris Kletzel; Donald Mahoney; Edward Newman; Yaddanapudi Ravindranath; Bruce Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2008-05       Impact factor: 1.289

5.  A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.

Authors:  Amir Mortazavi; Yonghua Ling; Ludmila Katherine Martin; Lai Wei; Mitch A Phelps; Zhongfa Liu; Erica J Harper; S Percy Ivy; Xin Wu; Bing-Sen Zhou; Xiyong Liu; Deidre Deam; J Paul Monk; William J Hicks; Yun Yen; Gregory A Otterson; Michael R Grever; Tanios Bekaii-Saab
Journal:  Invest New Drugs       Date:  2012-07-31       Impact factor: 3.850

6.  Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.

Authors:  T Szekeres; K Gharehbaghi; M Fritzer; M Woody; A Srivastava; B van't Riet; H N Jayaram; H L Elford
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149).

Authors:  Lode J Swinnen; Cathryn Rankin; Hetty Carraway; Kathy S Albain; Jeannette J Townsend; George Thomas Budd; Julie A Kish; Saul E Rivkin; Deborah T Blumenthal
Journal:  J Neurooncol       Date:  2007-11-16       Impact factor: 4.130

8.  Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772).

Authors:  P Heffeter; A Popovic-Bijelic; P Saiko; R Dornetshuber; U Jungwirth; N Voevodskaya; D Biglino; M A Jakupec; L Elbling; M Micksche; T Szekeres; B K Keppler; A Gräslund; W Berger
Journal:  Curr Cancer Drug Targets       Date:  2009-08-01       Impact factor: 3.428

9.  A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.

Authors:  Judith E Karp; Francis J Giles; Ivana Gojo; Lawrence Morris; Jacqueline Greer; Bonny Johnson; Mya Thein; Mario Sznol; Jennifer Low
Journal:  Leuk Res       Date:  2007-07-20       Impact factor: 3.156

10.  Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia.

Authors:  J L Yang; E H Cheng; R L Capizzi; Y C Cheng; T Kute
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.